



Aiosyn's Kidney AI Suite Revolutionizing kidney lesion analysis and CKD research with AI precision

AI-Powered solutions to assist researchers and pathologists in quantifying kidney lesion scores

Accelerate CKD therapy development with Aiosyn's Kidney AI Suite

Objective quantification of kidney lesion scores

Chronic Kidney Disease (CKD) affects around 850 million people worldwide and is predicted to become the fifth global cause of death by 2040. Histopathologic assessment of renal biopsies remains the gold standard for diagnosing and monitoring various kidney diseases.

Aiosyn's Kidney AI Suite harnesses AI-powered computational pathology algorithms that provide objective quantification of kidney lesion scores, presenting an opportunity to accelerate the drug development process.

Empowering biopharma and CROs to improve future therapy development




Tailored biomarker strategies for precision medicine in CKD

Aiosyn uses AI technology to enable the identification of new and existing CKD biomarkers and complement existing precision medicine projects to understand drivers of CKD and classify important CKD subgroups. These insights can improve personalized treatment of CKD patients.



Improved efficiency and reproducibility of clinical trials

AI-powered algorithms can decrease study review times by screening large volumes of slides and providing the pathologist with a reproducible tool for histological assessment of kidney biopsies within clinical trials.






How can we assist your team?


- AI-powered algorithms to quantify kidney lesion scores such as glomerular sclerotization and interstitial fibrosis.
- Objective quantification to improve the reproducibility of results.
- Support for pathologists' assessments in multi-center (pre-)clinical studies.
- Customized projects for new and existing biomarkers.

Examples of our solutions



Segmentation of main tissue classes

Our AI can accurately segment relevant kidney structures, among which: (sclerotic) glomeruli, proximal/distal/atrophic tubuli, arteries & capsule. Leveraging this data, we can provide a wide variety of quantitative and spatial measurements, such as the number of glomeruli in a biopsy or the tissue area consisting of interstitium.



AI-Powered quantification of fibrosis

Renal fibrosis is a key biomarker for CKD progression and for prognosis of kidney transplantation. Current scoring systems are based on crude semi-quantitative assessments, limited to the capability of the human eye. AI-based fibrosis quantification yields an objective and precise measurement that can aid pathologists and biopharma services with their assessments.



Localization and counting of glomeruli

Every renal biopsy undergoes an assessment of its glomeruli. Our AI-powered algorithms provide a quantitative glomerular count, boosting review efficiency and improving the reproducibility for Chronic Kidney Disease (CKD) treatment planning.



Toernooiveld 300
6525 EC Nijmegen
The Netherlands

contact@aiosyn.com
www.aiosyn.com

© Copyright 2023 Aiosyn. All rights reserved.

Product Disclosure: Aiosyn's Kidney AI Suite is for Research Use Only and should not be used for diagnostic procedures.